Zeng-Quan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zeng-Quan Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Cui Liu
College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China
1 shared publication Li-Min Chao
College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
1 shared publication- Shining Guo
College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
1 shared publication - Weijie Lv
College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
1 shared publication - Wen-Qian Chen
College of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong 510642, China
1 shared publication - Xiaolong Xu
Beijing Hospital of Traditional Chinese Medicine Capital Medical University Beijing China
1 shared publication
Latest Publications
- Open Access
- 23 June 2019
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-30
Systems Pharmacology and Microbiome Dissection of Shen Ling Bai Zhu San Reveal Multiscale Treatment Strategy for IBD
Generally, inflammatory bowel disease (IBD) can be caused by psychology, genes, environment, and gut microbiota. Therefore, IBD therapy should be improved to utilize multiple strategies. Shen Ling Bai Zhu San (SLBZS) adheres to the aim of combating complex diseases from an integrative and holistic perspective, which is effective for IBD therapy. Herein, a systems pharmacology and microbiota approach was developed for these molecular mechanisms exemplified by SLBZS. First, by systematic absorption-distribution-metabolism-excretion (ADME) analysis, potential active compounds and their corresponding direct targets were retrieved. Then, the network relationships among the active compounds, targets, and disease were built to deduce the pharmacological actions of the drug. Finally, an “IBD pathway” consisting of several regulatory modules was proposed to dissect the therapeutic effects of SLBZS. In addition, the effects of SLBZS on gut microbiota were evaluated through analysis of the V3-V4 region and multivariate statistical methods. SLBZS significantly shifted the gut microbiota structure in a rat model. Taken together, we found that SLBZS has multidimensionality in the regulation of IBD-related physiological processes, which provides new sights into herbal medicine for the treatment of IBD.
- 23 June 2019
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-30
Open AccessSystems Pharmacology and Microbiome Dissection of Shen Ling Bai Zhu San Reveal Multiscale Treatment Strategy for IBD
Generally, inflammatory bowel disease (IBD) can be caused by psychology, genes, environment, and gut microbiota. Therefore, IBD therapy should be improved to utilize multiple strategies. Shen Ling Bai Zhu San (SLBZS) adheres to the aim of combating complex diseases from an integrative and holistic perspective, which is effective for IBD therapy. Herein, a systems pharmacology and microbiota approach was developed for these molecular mechanisms exemplified by SLBZS. First, by systematic absorption-distribution-metabolism-excretion (ADME) analysis, potential active compounds and their corresponding direct targets were retrieved. Then, the network relationships among the active compounds, targets, and disease were built to deduce the pharmacological actions of the drug. Finally, an “IBD pathway” consisting of several regulatory modules was proposed to dissect the therapeutic effects of SLBZS. In addition, the effects of SLBZS on gut microbiota were evaluated through analysis of the V3-V4 region and multivariate statistical methods. SLBZS significantly shifted the gut microbiota structure in a rat model. Taken together, we found that SLBZS has multidimensionality in the regulation of IBD-related physiological processes, which provides new sights into herbal medicine for the treatment of IBD.